➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
McKesson
Express Scripts
Medtronic

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Filgrastim - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for filgrastim

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Genentech, Inc.Phase 1
University of WashingtonPhase 1
Agios PharmaceuticalsPhase 1

See all filgrastim clinical trials

Recent Litigation for filgrastim

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.2018-06-19
CELGENE CORPORATION v. HETERO LABS LIMITED2017-05-11

See all filgrastim litigation

PTAB Litigation
PetitionerDate
2016-09-15
2012-09-25

See all filgrastim litigation

Company Disclosures: US Patents for filgrastim

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Kirin- Amgen Inc. (Thousand Oaks, CA) 2006-03-07 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2005-08-23 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-10 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Kirin- Amgen Inc. (Thousand Oaks, CA) 2006-03-07 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for filgrastim

These patents were identified by searching patent claims

Supplementary Protection Certificates for filgrastim

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/048 Ireland   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140522
/2014 Austria   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928 20140522
1562968/01 Switzerland   Start Trial FORMER OWNER: JANSSEN BIOTECH, INC., US
6 Finland   Start Trial
90007-0 Sweden   Start Trial PRODUCT NAME: LIPEFILGRASTIM; REG. NO/DATE: EU/1/13/856 20130725
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Moodys
Dow
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.